Trial Type: Liver and Bile Duct Cancer

CAST
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360, a TOP1i ADC Targeting Claudin 18.2 (CLDN18.2) in Adult Participants with Advanced Solid Tumors
Contact: Alex Raufi, MD
LS-P-ROSE
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC
Status: Open
Contact: Khaldoun Almhanna, MD
GPC3CD3 Trial
A phase 1/2 study of SAR444200, an anti-GPC3/CD3 bispecific antibody in patients with advanced solid tumors
Contact: Khaldoun Almhanna, MD
PORT
GPC3/CD3 bispecific antibody for all solid tumors with GPC3 expression.
Status: Open
Contact: Khaldoun Almhanna, MD